Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.

Hepatology 2010 Feb;51(2):615-20

Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Unlabelled: Reactive metabolites generated by hepatic metabolism are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited. If this is true, then compounds with significant hepatic metabolism should cause more DILI than those without it. We conducted a study to examine the relationship between hepatic metabolism and DILI of prescription medications. We systematically extracted the metabolism characteristics of 207 of the most widely prescribed oral medications in the United States. Compounds with >50% hepatic metabolism were characterized as those with significant hepatic metabolism (n = 149). Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI. Compared with compounds with lesser hepatic metabolism, compounds belonging to the significant hepatic metabolism group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% versus 11%, P = 0.001), liver failure (28% versus 9%, P = 0.004), and fatal DILI (23% versus 4%, P = 0.001), but not jaundice (46% versus 35%, P = 0.2) or liver transplantation (9% versus 2%, P = 0.11). Twelve compounds with no hepatic metabolism had no reports of liver failure, liver transplantation, or fatal DILI. When the relationship between hepatic adverse events and combination of hepatic metabolism and daily dose was examined, compounds with both significant hepatic metabolism and daily dose >50 mg (n = 50) were significantly more hepatotoxic than compounds belonging to other groups. Compared with medications without biliary excretion, compounds with biliary excretion (n = 50) had significantly higher frequency of jaundice (74% versus 40%, P = 0.0001).

Conclusion: Our study finds an important relationship between a compound's metabolism profile and reports of hepatic adverse events.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.23317DOI Listing
February 2010
10 Reads

Publication Analysis

Top Keywords

hepatic metabolism
44
hepatic adverse
16
adverse events
16
hepatic
15
metabolism
13
liver failure
12
compounds hepatic
12
liver transplantation
12
fatal dili
12
alanine aminotransferase
8
compounds belonging
8
relationship hepatic
8
transplantation fatal
8
biliary excretion
8
failure liver
8
compounds
8
limit normal
8
times upper
8
daily dose
8
metabolism daily
8

References

(Supplied by CrossRef)

Gibson et al.
2001
Drug-induced liver injury
Abboud et al.
Drug Saf 2007
Drug-related hepatotoxicity
Navarro et al.
N Engl J Med 2006

Watkins et al.
2003
Studies on cytochrome P-450 mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites
Tang et al.
Drug Metab Dispos 1999

Similar Publications